Naema Nayyar

Naema Nayyar

Auto-generated profile, based on publicly available information

Naema Nayyar

Department of Medicine, Harvard Medical School & Massachusetts General Hospital, Boston, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DSDavid J. H. Shih
David J. H. Shih
NNNaema Nayyar
Naema Nayyar
IBIvanna Bihun
Ivanna Bihun
IDIbiayi Dagogo-Jack
Ibiayi Dagogo-Jack
CGCorey M. Gill
Corey M. Gill
PBPriscilla K. Brastianos
Priscilla K. Brastianos

5 February 2019 in Blood Advances
Verified
Journal Article
Closed access
NNNaema Nayyar
Naema Nayyar
MWMichael D. White
Michael D. White
CGCorey M. Gill
Corey M. Gill
MLMatthew Lastrapes
Matthew Lastrapes
MBMia Bertalan
Mia Bertalan
TBTracy T. Batchelor
Tracy T. Batchelor
The genetic alterations that define primary central nervous system lymphoma (PCNSL) are incompletely elucidated, and the genomic evolution from diagnosis to relapse is poorly understood. We performed whole-exome sequencing (WES) on 36 PCNSL patients and targeted MYD88 sequencing on a validation cohort of 27 PCNSL patients. We also performed WES and phylogenetic analysis of 3 matched newly diagnosed and relapsed tumor specimens and 1 synchronous intracranial and extracranial relapse. Immunohistochemistry (IHC) for programmed death-1 ligand (PD-L1) was performed on 43 patient specimens. Combined WES and targeted sequencing identified MYD88 mutation in 67% (42 of 63) of patients, CDKN2A biallelic loss in 44% (16 of 36), and CD79b mutation in 61% (22 of 36). Copy-number analysis demonstrated frequent regions of copy loss (ie, CDKN2A), with few areas of amplification. CD79b mutations were associated with improved progression-free and overall survival. We did not identify amplification at the PD-1/PD-L1 loci. IHC for PD-L1 revealed membranous expression in 30% (13 of 43) of specimens. Phylogenetic analysis of paired primary and relapsed specimens identified MYD88 mutation and CDKN2A loss as early clonal events. PCNSL is characterized by frequent mutations within the B-cell receptor and NF-κB pathways. The lack of PD-L1 amplifications, along with membranous PD-L1 expression in 30% of our cohort, suggests that PD-1/PD-L1 inhibitors may be useful in a subset of PCNSL. WES of PCNSL provides insight into the genomic landscape and evolution of this rare lymphoma subtype and potentially informs more rational treatment decisions.

14 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
PBPriscilla K. Brastianos
Priscilla K. Brastianos
AKAlbert E. Kim
Albert E. Kim
AGAnita Giobbie-Hurder
Anita Giobbie-Hurder
ELEudocia Quant Lee
Eudocia Quant Lee
NWNancy Wang
Nancy Wang
SSSandro Santagata
Sandro Santagata
High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their aggressive phenotype. Here, we present the results of a single-arm, open-label phase 2 trial (NCT03279692) evaluating the efficacy of pembrolizumab, a PD-1 inhibitor, in a cohort of 25 evaluable patients with recurrent and progressive grade 2 and 3 meningiomas. The primary endpoint is the proportion of patients alive and progression-free at 6 months (PFS-6). Secondary endpoints include progression-free and overall survival, best intracranial response, and toxicity. Our study has met its primary endpoint and achieved a PFS-6 rate of 0.48 (90% exact CI: 0.31–0.66) and a median PFS of 7.6 months (90% CI: 3.4–12.9 months). Twenty percent of patients have experienced one (or more) grade-3 or higher treatment-related adverse events. These results suggest that pembrolizumab exerts promising efficacy on a subset of these tumors. Further studies are needed to identify the biological facets within the meningioma TME that may drive response to immune-based therapies.

12 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
PBPriscilla K. Brastianos
Priscilla K. Brastianos
MSMatthew R. Strickland
Matthew R. Strickland
ELEudocia Quant Lee
Eudocia Quant Lee
NWNancy Wang
Nancy Wang
JCJustine V. Cohen
Justine V. Cohen
RSRyan J. Sullivan
Ryan J. Sullivan
Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with a poor prognosis and limited treatment options. We present a single arm Phase II study of 18 patients with LMD receiving combined ipilimumab and nivolumab until progression or unacceptable toxicity (NCT02939300). The primary end point is overall survival at 3 months (OS3). Secondary end points include toxicity, cumulative time-to-progression at 3 months, and progression-free survival. A Simon two-stage design is used to compare a null hypothesis OS3 of 18% against an alternative of 44%. Median follow up based on patients still alive is 8.0 months (range: 0.5 to 15.9 months). The study has met its primary endpoint as 8 of 18 (OS3 0.44; 90% CI: 0.24 to 0.66) patients are alive at three months. One third of patients have experienced one (or more) grade-3 or higher adverse events. Two patients have discontinued protocol treatment due to unacceptable toxicity (hepatitis and colitis, respectively). The most frequent adverse events include fatigue (N = 7), nausea (N = 6), fever (N = 6), anorexia (N = 6) and rash (N = 6). Combined ipilimumab and nivolumab has an acceptable safety profile and demonstrates promising activity in LMD patients. Larger, multicenter clinical trials are needed to validate these results.

12 October 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSanjay M. Prakadan
Sanjay M. Prakadan
CAChristopher A. Alvarez-Breckenridge
Christopher A. Alvarez-Breckenridge
SMSamuel C. Markson
Samuel C. Markson
AKAlbert E. Kim
Albert E. Kim
RKRobert H. Klein
Robert H. Klein
ASAlex K. Shalek
Alex K. Shalek
Leptomeningeal disease (LMD) is a devastating complication of solid tumor malignancies, with dire prognosis and no effective systemic treatment options. Over the past decade, the incidence of LMD has steadily increased due to therapeutics that have extended the survival of cancer patients, highlighting the need for new interventions. To examine the efficacy of immune checkpoint inhibitors (ICI) in patients with LMD, we completed two phase II clinical trials. Here, we investigate the cellular and molecular features underpinning observed patient trajectories in these trials by applying single-cell RNA and cell-free DNA profiling to longitudinal cerebrospinal fluid (CSF) draws from enrolled patients. We recover immune and malignant cell types in the CSF, characterize cell behavior changes following ICI, and identify genomic features associated with relevant clinical phenomena. Overall, our study describes the liquid LMD tumor microenvironment prior to and following ICI treatment and demonstrates clinical utility of cell-free and single-cell genomic measurements for LMD research.

15 June 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
CAChristopher Alvarez-Breckenridge
Christopher Alvarez-Breckenridge
SMSamuel C. Markson
Samuel C. Markson
JSJackson H. Stocking
Jackson H. Stocking
NNNaema Nayyar
Naema Nayyar
MLMatt Lastrapes
Matt Lastrapes
SCScott L. Carter
Scott L. Carter
Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity against MBM; however, the MBM tumor microenvironment (TME) has not been fully elucidated in the context of ICI. To dissect unique elements of the MBM TME and correlates of MBM response to ICI, we collected 32 fresh MBM and performed single-cell RNA sequencing of the MBM TME and T-cell receptor clonotyping on T cells from MBM and matched blood and extracranial lesions. We observed myeloid phenotypic heterogeneity in the MBM TME, most notably multiple distinct neutrophil states, including an IL8-expressing population that correlated with malignant cell epithelial-to-mesenchymal transition. In addition, we observed significant relationships between intracranial T-cell phenotypes and the distribution of T-cell clonotypes intracranially and peripherally. We found that the phenotype, clonotype, and overall number of MBM-infiltrating T cells were associated with response to ICI, suggesting that ICI-responsive MBMs interact with peripheral blood in a manner similar to extracranial lesions. These data identify unique features of the MBM TME that may represent potential targets to improve clinical outcomes for patients with MBM.